Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Medicine Of Ukraine 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.Peer-Reviewed Original ResearchIncidence rate ratiosT2D patientsClinical trialsStone eventsGLP-1 receptor agonistsLarge cardiovascular outcome trialsEMPA-REG OUTCOMESGLT2 inhibitor empagliflozinCardiovascular outcome trialsProspective clinical trialsSGLT2 inhibitor useRisk of nephrolithiasisAnnual incidence rateRandomized clinical trialsType 2 diabetesRelative risk estimatesEmpagliflozin therapyInhibitor empagliflozinInhibitor useOutcome trialsDiabetes mellitusSGLT2 inhibitionReceptor agonistRisk factorsIncidence rate